Home / Resource Library / Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology
Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology